Drug intelligence / Profile preview

GS-1219

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral, Parenteral

Overview

GS-1219 is a **small molecule HIV-1 integrase strand transfer inhibitor (INSTI)** developed by Gilead Sciences for the treatment of HIV infections. The drug is intended to block HIV integrase, an essential viral enzyme responsible for integrating the viral genome into the host cell DNA, thus inhibiting HIV replication. GS-1219 is in early clinical development phases, with its highest reported status in Phase I trials. There is no orphan drug designation, and it is considered an antiretroviral agent, specifically within the integrase inhibitor subclass. GS-1219 is a new molecular entity and is administered orally and parenterally. Combination therapy trials have also been initiated[1][3].

Brand names: GS-1219GS1219GS 1219
Other names: GS-1219GS1219GS 1219

Targets

Integrase allosteric pocket (HIV)

Beyond the preview

Go deeper on GS-1219.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-1219.

Explore the full profile